Compare RITM & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RITM | GH |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 14.1B |
| IPO Year | N/A | 2018 |
| Metric | RITM | GH |
|---|---|---|
| Price | $11.13 | $101.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | $14.25 | ★ $82.76 |
| AVG Volume (30 Days) | ★ 5.2M | 2.2M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 9.00% | N/A |
| EPS Growth | ★ 46.96 | N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $3,961,432,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $34.72 |
| Revenue Next Year | $8.20 | $26.46 |
| P/E Ratio | $7.66 | ★ N/A |
| Revenue Growth | ★ 32.03 | 30.38 |
| 52 Week Low | $9.13 | $29.91 |
| 52 Week High | $12.74 | $112.43 |
| Indicator | RITM | GH |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 55.40 |
| Support Level | $10.98 | $100.21 |
| Resistance Level | $11.32 | $109.59 |
| Average True Range (ATR) | 0.19 | 4.22 |
| MACD | -0.02 | -1.65 |
| Stochastic Oscillator | 23.20 | 13.51 |
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.